Currently, active public health surveillance of hyperbilirubinemia and kernicterus is lacking. Recently, the Hospital Corporation of America (HCA), a private health care system with an estimated quarter of a million births annually, instituted recommendations to provide universal hyperbilirubinemia screening before discharge for all infants born within their system. Over 98% of the infants born at HCA hospitals were screened within the first year of the recommendations. From May to December 2004, 13 infants were identified with total serum bilirubin (TSB) X30 mg per 100 ml, but that number was reduced in 2006, with only seven infants born in HCA hospitals developing a TSB of X30 mg per 100 ml. This program provides a model for actively monitoring the occurrence of hyperbilirubinemia and for tracking its occurrence, thus improving health care quality for patients while collecting important public health information.
Introduction
Infant jaundice is not rare. In fact, about 60% of otherwise healthy term infants will experience jaundice and about 10% of them will require some form of treatment (phototherapy or exchange transfusions). 1, 2 Jaundice is caused by hyperbilirubinemia, a build-up of bilirubin in the blood, and treatment to reduce bilirubin is highly effective. However, when severe hyperbilirubinemia is not properly managed, a rare and permanent form of brain damage called kernicterus can occur.
Kernicterus is manifested as various conditions and can cause choreoathetoid cerebral palsy, hearing and vision loss and dental dysplasia, and can even lead to mortality in severe cases. 3 The true incidence of kernicterus in the United States remains undocumented as there is currently no national surveillance for hyperbilirubinemia. Nonetheless, growing membership in a Kernicterus Registry and an international family support group, Parents of Infants and Children with Kernicterus (PICK), indicates that cases of kernicterus continue to emerge and infants are falling through gaps in health care provision. [4] [5] [6] To make systematic changes in the health care of newborns, we must address these gaps through a multifaceted approach. Not only should we engage the traditional conduit, our health care providers, but we also need to involve the broader network of infant and child care providers, including parents and the greater public health community. Together, these communities can appropriately address gaps in hyperbilirubinemia management. 7 Systemic change requires establishing best practices, encouraging early diagnosis through timely examinations of infant risk factors for hyperbilirubinemia, and providing practical educational materials for expecting parents and woman of childbearing age. Monitoring the occurrence of hyperbilirubinemia and kernicterus rounds out the picture by providing evidence of the changes in rates and by measuring the sustainability of prevention efforts.
Public awareness
Most parents will learn something about jaundice before their newborns leave the hospital for the first time. Yet, most parents do not know the dangers of severe newborn jaundice or hyperbilirubinemia. A 2005 HealthStyles survey asked 12 639 respondents two questions relating to kernicterus. When asked, 'Have you ever heard of kernicterus (a complication of newborn jaundice)?', 71.9% of the respondents replied 'no' and 72.1% of the female respondents aged 18 to 44 years also replied 'no.' When the female respondents were asked, 'Do you think that jaundice in a newborn baby can cause brain damage?', 59.1% were 'not sure' and only 17.0% replied 'yes.' 8 Even though the consequences of severe jaundice are well documented in the medical community, there seems to be less concern and knowledge among the general population about the consequences of severe, untreated hyperbilirubinemia. Paradoxically, this might be a result of success in treating newborn jaundice.
Health care providers
Various factors have influenced recommendations for the management of hyperbilirubinemia and outcomes for newborns. 1, 3, 9 Before the mid 1970s, newborn infants had longer hospital stays, staying on an average of 4.1 days after delivery. This allowed the necessary time for infants who might develop jaundice to be observed by health care providers. However, by 1992 this length of stay had decreased to 2.6 days after delivery. [10] [11] [12] By the 1990s, attitudes toward hyperbilirubinemia in late-preterm (34 to 36 weeks) and full-term (37 to 42 weeks) infants relaxed, as some felt that too many infants were being treated unnecessarily. Full-term healthy infants without risk factors for hemolysis were no longer considered at risk for hyperbilirubinemia. 9 At the same time that attitudes toward hyperbilirubinemia relaxed, new hospital policies that influenced management of hyperbilirubinemia practices were taking place. It was becoming standard for healthy late-preterm and full-term infants to be discharged as early as 12 to 24 h after an uncomplicated vaginal birth and 48 to 72 h after an uncomplicated caesarian section. This later became known as 'the drive-through delivery' phenomenon. 10, 12, 13 As bilirubin often peaks after this period, usually 3 to 5 days after birth, shorter hospital stays for newborns reduced the ability of hospital health care providers to identify hyperbilirubinemia. In addition, more women were recognizing the overwhelming benefits of breastfeeding. Breastfeeding provides optimal nutrition for infants, but improper breastfeeding techniques (which can be exacerbated by insufficient lactation support in the perinatal period after delivery) can lead to inadequate newborn hydration that reduces an infant's ability to excrete bilirubin, which can lead to hyperbilirubinemia. Consequently, concerns about a reemergence of kernicterus began to arise.
Translating policy into practice
The leap from evidence-based science to policy and practice is integral to closing the gaps in hyperbilirubinemia management. In 2001, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) put out the first sentinel event alert about hyperbilirubinemia.
14 The Centers for Disease Control and Prevention (CDC) published a Mortality and Morbidity Weekly Report (MMWR) documenting a reemergence of kernicterus cases, 5 and funded two pilot projects focused on kernicterus research and prevention. The American Academy of Pediatrics (AAP) responded by publishing The Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks Gestation.
3 These 2004 guidelines describe specific risk factors that should be evaluated and identified before a newborn infant's initial hospital discharge. 1, 3, 7 PICK and other organizations have advocated that universal bilirubin screening should be mandated and carried out at the same time as universal newborn screening samples are obtained, generally before an otherwise healthy infant's 48 h discharge.
Implementation
In response to these various recommendations, the Hospital Corporation of America (HCA) initiated a program that links individual health care delivery and public health surveillance for hyperbilirubinemia. The CDC interviewed members of the HCA to investigate the feasibility of their program as a surveillance system. We used information from those interviews and data released by HCA to develop this report.
Hospital Corporation of America is a large, private health care system with hospitals in 23 states across the United States and an estimated quarter of a million births annually. In March 2004, before the release of the new AAP guidelines, the HCA convened a task force of experts in the field of hyperbilirubinemia and kernicterus. The task force was charged to design an efficient and effective policy to prevent kernicterus. They worked closely with members of the AAP and elicited further input from the HCA neonatologists, pediatricians, nurses and lactation consultants in producing the new policy recommendations.
By May 2005, the HCA had implemented universal screening practices for managing hyperbilirubinemia for all infants born in its system. The recommended practice calls for network hospitals not to rely on a visual assessment but, instead, perform a transcutaneous bilirubin (TcB) test or a total serum bilirubin (TSB) test on all newborns before hospital discharge. Screening through TcB measurement devices allows for an easy non-invasive method to assess level of risk. The HCA supplies all of their birthing hospitals with TcB bilimeters. The recommended practice also suggests that any TcB above 15 mg per 100 ml be confirmed by a TSB blood sample test, which provides a more reliable estimate for levels that meet the criteria for hyperbilirubinemia. Assessment for risk factors is also a recommended procedure. Recommendations for treatment, including phototherapy and exchange transfusions, as well as follow-up appointments for high-risk infants, are in accordance with the AAP guidelines (see Table 1 ).
Surveillance and public health impact HCA measures the impact of its recommendations using a centralized database that converts all laboratory reports from their various hospitals and provides surveillance data on hyperbilirubinemia. A monthly report from each hospital is generated, delineating the number of infants younger than 29 days of age with TSB levels recorded at X18 mg per 100 ml. This report serves as both quality control and monitoring for all infants born >35 weeks at HCA hospitals. A second level of quality control and monitoring requires that the hospitals review infant records with Table 1 Recommendations for initial follow-up appointment after newborn hospital discharge 3 
Infants discharged by age
Should receive a pediatric follow-up 24 h 2 days post discharge 24-47.9 h 2-3 days post discharge 48-72 h 3-4 days post discharge bilirubin levels >25 mg per 100 ml. These records are also identified and sent to the HCA headquarters for review. As a result of this new initiative, a private hospital corporation is providing a service both directly to their patients and to the public health community. By analyzing their surveillance data, the HCA is able to track increase or decrease in the number of newborns with high bilirubin levels across their large hospital consortium. Initial results suggest a decrease in cases associated with this initiative.
Within 1 year of instituting these recommendations, over 98% of newborns at HCA birthing hospitals were screened. From May to December 2004, 13 infants (of 149 831 births) were identified with TSB X30 mg per 100 ml. However, by 2006, after implementing the new recommendations, only seven infants (of 225 216 births) born in HCA hospitals had progressed to TSB X30 mg per 100 ml. After increased vigilance for risk factors for hyperbilirubinemia, the number of infants with hemolytic disease treated in the emergency department increased by 13.5% from 2003 to 2005. Without data prior to these recommendations, HCA cannot estimate the magnitude of the effect that this has had on their patient population; however, it is encouraging to witness the improvements that are being made in patient care and safety. 15 Kernicterus continues to occur despite its preventability. A new understanding of contemporary hospital practicesFcombined with guidelines that clearly define risk factors for assessment and procedures, as well as technology that includes non-invasive TcB, and standardized measures of hyperbilirubinemia risk (nomogram)Fare helping to prevent severe hyperbilirubinemia and kernicterus. The combination of new policies and practices, developed from evidence-based science, makes filling the gaps in hyperbilirubinemia management feasible. Changes are underway in hospitals across the United States to make sure that not one case of kernicterus develops from untreated severe jaundice.
